Patients with metastatic colorectal cancer may be eligible for a new investigational anti-angiogenesis study at the University of Minnesota Cancer Center. The drug, SU 5416, is a man-made molecule that is delivered to the patient intravenously. Only patients with metastatic colorectal cancer, the stage in which cancer cells have spread to other parts of the body, may enroll in this clinical trial. David Rothenberger, M.D, clinical professor and director of the division of colon and rectal surgery and associate director for clinical research at the university s Cancer Center, will serve as principal investigator in the study. Arek Dudek and Ed Greeno, medical oncologists at the University of Minnesota, will assist with the trial.
Colorectal cancer is the second leading cause of cancer deaths in the United States.
Colorectal cancer, if caught early, can be one of the most curable and preventable cancers. Last updated March 30, 2000. Specific advice on diagnosing or treating a health care problem should be obtained from your health care provider. The University of Minnesota is an equal opportunity educator and employer.